Myrexis, Inc. (Formerly Known as Myriad Pharmaceuticals, Inc.) to Provide Update on Heat Shock Protein 90 and Cancer Metabolism Inhibitor Programs at 102nd Annual Meeting of American Association for Cancer Research

SALT LAKE CITY, March 17, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it will present nine posters at the 102nd annual meeting of the American Association for Cancer Research (AACR), April 2 – 6, 2011, in Orlando, Florida.